Avanafil,
does it really help with Improvement in IIEF erectile function, penetration success on SEP2, and intercourse success on SEP3 in men with erectile dysfunction?
research showsAvanafil is rated B because it consistently improves IIEF erectile function, penetration success, and intercourse success in men with erectile dysfunction. Across eight randomized trials involving 3,709 participants, IIEF-EF improved by 4.57 points, SEP2 had a risk ratio of 3.20, and SEP3 had a risk ratio of 2.53. In a direct comparison with sildenafil, avanafil was noninferior at four weeks and superior at eight and twelve weeks. IIEF and SEP are direct patient-function outcomes and treatment targets, not surrogates. Manufacturer concentration remains a limitation, but the scale and consistency are comparable to the B-rated vardenafil evidence, supporting B with 72 points.
ads claimSimplified messaging can promise natural erections for everyone within 15 minutes, prolonged performance, and almost no adverse effects. Sexual stimulation is required, some men do not respond, onset is affected by food, alcohol, disease, and concomitant drugs, and treatment does not replace evaluation of the underlying cause.
Useful facts when choosing a product
- Avanafil is an as-needed prescription drug that facilitates an erectile response in the presence of sexual stimulation. A common starting dose is 100 mg approximately 15 to 30 minutes before sexual activity, but the Korean product label and prescription determine exact dose, timing, and a maximum of once daily.
- Combining avanafil with a nitrate or nitric oxide donor can cause life-threatening hypotension and is contraindicated. Alpha blockers, other blood-pressure medicines, and strong CYP3A4 inhibitors require medical review.
- Headache, flushing, nasal congestion, and dizziness can occur. Sudden loss of vision or hearing requires stopping the drug and urgent medical care, and people for whom sexual activity is unsafe because of cardiovascular disease need prior assessment.
- An erection lasting four hours or longer is an emergency. Other phosphodiesterase type 5 inhibitors or erectile-dysfunction treatments should not be combined without direction, and emergency clinicians treating chest pain must be told when the last avanafil dose was taken.
What the research actually shows
Goldstein 2012 randomized 646 men with mild to severe erectile dysfunction for twelve weeks to placebo or avanafil 50, 100, or 200 mg. Changes in SEP2 and SEP3 success and IIEF-EF favored every dose over placebo. Zhao 2012 randomized 200 Korean men with erectile dysfunction to placebo, 100 mg, or 200 mg and reproduced the primary IIEF-EF outcome and SEP2 and SEP3 benefits. Li 2019 synthesized eight randomized trials with 3,709 participants and estimated risk ratios of 3.20 for successful vaginal penetration and 2.53 for successful intercourse and a 4.57-point mean IIEF-EF advantage. Both 100 and 200 mg were generally effective, but the incremental high-dose benefit varied by outcome, and short duration and concentrated industry funding limit long-term durability and independent replication.
Why this is classified as B (72)
Eight randomized trials involving 3,709 participants consistently found an IIEF-EF gain of 4.57 points, a SEP2 risk ratio of 3.20, and a SEP3 risk ratio of 2.53; a direct sildenafil comparison found noninferiority at four weeks and superiority at eight and twelve weeks. IIEF and SEP are direct patient-function outcomes and treatment targets rather than surrogates. Manufacturer concentration remains a limitation, but the scale and replication are comparable to the B-rated vardenafil evidence, supporting B with 72 points. Safety issues remain separate.
Counterpoint. For an appropriately prescribed man with erectile dysfunction and no contraindication, avanafil offers a relatively rapid as-needed option. Repeated failure should prompt review of administration, underlying disease, and alternatives rather than unsupervised dose stacking.
Rejudgment record. Consistency recalibration (rule 1 clarification) — Treated IIEF-EF, SEP2, and SEP3 as direct patient-function outcomes and treatment targets rather than surrogates; consistent improvement across eight trials involving 3,709 participants, a direct sildenafil comparison, and evidence strength comparable to B-rated vardenafil support B
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improvement in the IIEF erectile-function domain | B | This direct treatment-target outcome improved consistently by a mean 4.57 points across eight randomized trials. |
| Improvement in penetration success on SEP2 | B | SEP2 is a direct patient-function outcome and improved consistently across multiple trials, with a risk ratio of 3.20. |
| Improvement in intercourse success on SEP3 | B | SEP3 is a direct patient-function outcome and improved consistently across multiple trials, with a risk ratio of 2.53. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Goldstein I et al. 2012 | Twelve-week multicenter randomized double-blind placebo-controlled phase 3 trial | 646 | VIVUS product-development study with employee coauthorship | IIEF-EF, penetration success on SEP2, and intercourse success on SEP3 | All avanafil doses of 50, 100, and 200 mg significantly improved all three outcomes versus placebo. | Large direct product trial with functional outcomes |
| Zhao C et al. 2012 Korean phase 3 trial | Twelve-week multicenter randomized double-blind placebo-controlled fixed-dose phase 3 trial | 200 | Industry product-development trial | Change in IIEF-EF as the primary outcome; SEP2 and SEP3 as secondary outcomes | Both 100 mg and 200 mg significantly improved IIEF-EF, SEP2, and SEP3 versus placebo. | Direct replication trial in Korean participants |
| Li J et al. 2019 | Systematic review and meta-analysis of randomized trials | 3,709 | Academic meta-analysis; included trials were predominantly industry funded | Successful vaginal penetration, successful intercourse, IIEF-EF, and treatment adverse events | Versus placebo, the risk ratio was 3.20 for penetration and 2.53 for successful intercourse, with a 4.57-point mean IIEF-EF advantage. | Synthesis of repeated direct functional outcomes |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-23).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none
Cite this verdict
[Chamgap] Avanafil x improved IIEF, penetration, and intercourse success in erectile dysfunction — Evidence Grade B·72. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/mens/avanafil-men-erectile-dysfunction-iief-sep2-sep3/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.